Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35050314.
- Also identified by DOI 10.1001/jama.2022.0210 and PMC identifier 8778597.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examines breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in March-August 2021, when the Delta variant predominated, among a general US cohort vaccinated with mRNA-1273 or BNT162b2.
Medical subject headings
- 2019-nCoV Vaccine mRNA-1273
- BNT162 Vaccine
- COVID-19
- SARS-CoV-2